Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

[{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$4.0 million","newsHeadline":"CURE Pharmaceutical Closes $10 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical to Present at H.C. Wainwright 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Milagro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children\u2019s Hospital Medical Center (CCHMC) Using CURE\u2019s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Tran","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Cure Pharmaceutical

Cure Pharmaceutical

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

21 News

21 News

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High,...

Details:

CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease.

Lead Product(s): Vitamin D3

Therapeutic Area: Nutrition and Weight Loss Product Name: ImmunD3 Nutri-Strips

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2022

ASK
US

Upload
your Pipeline Activity

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico

Details:

Collaboration will sell in Mexico a number of CURE’s OTC and medical compounds (sildenafil citrate) that utilize CUREform™, CURE’s patented drug delivery platform for oral thin film (OTF). Cure is in discussions with several large distributors in Mexico and Latin America.

Lead Product(s): Sildenafil Citrate

Therapeutic Area: Psychiatry/Psychology Product Name: CUREfilm Blue

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Milagro Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 03, 2022

ASK
US

Upload
your Pipeline Activity

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical to Present at H.C. Wainwright 2021

Details:

CURE Pharmaceutical is the pioneering developer of CUREform, patented drug delivery platform that offers a no. of unique immediate & controlled-release drug delivery vehicles designed to improve drug efficacy, safety & patient experience for a wide range of active ingredients.

Lead Product(s): Tetrahydrocannabinol,Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: Canna

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

ASK
US

Upload
your Pipeline Activity

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue™

Details:

CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate.

Lead Product(s): Sildenafil Citrate

Therapeutic Area: Psychiatry/Psychology Product Name: CUREfilm Blue

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2021

ASK
US

Upload
your Pipeline Activity

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical Closes $10 Million Financing

Details:

Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline

Lead Product(s): Sildenafil Citrate

Therapeutic Area: Endocrinology Product Name: CUREfilm Blue

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Axiom Capital Management

Deal Size: $10.0 million Upfront Cash: $4.0 million

Deal Type: Financing November 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY